You have selected a link to a third-party Web site. This link is provided solely as a convenience to you and not as an endorsement by EMD Serono, Inc. of such third-party Web site. EMD Serono is not responsible for and does not make any representations regarding the accuracy of materials on such third-party site.
You have selected a link to a third-party Web site. This link is provided solely as a convenience to you and not as an endorsement by EMD Serono, Inc. of such third-party Web site. EMD Serono is not responsible for and does not make any representations regarding the accuracy of materials on such third-party site.
You have selected a link to a third-party Web site. This link is provided solely as a convenience to you and not as an endorsement by EMD Serono, Inc. of such third-party Web site. EMD Serono is not responsible for and does not make any representations regarding the accuracy of materials on such third-party site.
You have selected a link to a third-party Web site. This link is provided solely as a convenience to you and not as an endorsement by EMD Serono, Inc. of such third-party Web site. EMD Serono is not responsible for and does not make any representations regarding the accuracy of materials on such third-party site.
You have selected a link to a third-party Web site. This link is provided solely as a convenience to you and not as an endorsement by EMD Serono, Inc. of such third-party Web site. EMD Serono is not responsible for and does not make any representations regarding the accuracy of materials on such third-party site.
You have selected a link to a third-party Web site. This link is provided solely as a convenience to you and not as an endorsement by EMD Serono, Inc. of such third-party Web site. EMD Serono is not responsible for and does not make any representations regarding the accuracy of materials on such third-party site.
You have selected a link to a third-party Web site. This link is provided solely as a convenience to you and not as an endorsement by EMD Serono, Inc. of such third-party Web site. EMD Serono is not responsible for and does not make any representations regarding the accuracy of materials on such third-party site.
You have selected a link to a third-party Web site. This link is provided solely as a convenience to you and not as an endorsement by EMD Serono, Inc. of such third-party Web site. EMD Serono is not responsible for and does not make any representations regarding the accuracy of materials on such third-party site.
You have selected a link to a third-party Web site. This link is provided solely as a convenience to you and not as an endorsement by EMD Serono, Inc. of such third-party Web site. EMD Serono is not responsible for and does not make any representations regarding the accuracy of materials on such third-party site.
You have selected a link to a third-party Web site. This link is provided solely as a convenience to you and not as an endorsement by EMD Serono, Inc. of such third-party Web site. EMD Serono is not responsible for and does not make any representations regarding the accuracy of materials on such third-party site.
You have selected a link to a third-party Web site. This link is provided solely as a convenience to you and not as an endorsement by EMD Serono, Inc. of such third-party Web site. EMD Serono is not responsible for and does not make any representations regarding the accuracy of materials on such third-party site.
You have selected a link to a third-party Web site. This link is provided solely as a convenience to you and not as an endorsement by EMD Serono, Inc. of such third-party Web site. EMD Serono is not responsible for and does not make any representations regarding the accuracy of materials on such third-party site.
Gonal-f® Cares about the needs of all fertility patients. Besides Gonal-f®, there are a variety of EMD Serono medications available to help treat infertility. Select a video below to learn more about dosage and administration.
Prescribing Information and Important Safety Information:
Luveris® (lutropin alfa for injection), concomitantly administered with Gonal-f® (follitropin alfa for injection), is indicated for the stimulation of follicular development in infertile hypogonadotropic hypogonadal women with profound LH deficiency. A definitive effect on pregnancy in this population has not been demonstrated. Luveris should only be prescribed by doctors specializing in infertility or reproductive health. Luveris can cause serious side effects including: Ovarian hyperstimulation syndrome (OHSS), with or without blood vessel and lung problems and multiple births. Luveris® (lutropin alfa for injection) is contraindicated in women who exhibit, prior hypersensitivity to hLH preparations or one of their excipients, primary ovarian failure, uncontrolled thyroid or adrenal dysfunction, an uncontrolled organic intracranial lesion such as a pituitary tumor, abnormal uterine bleeding of undetermined origin, ovarian cyst or enlargement of undetermined origin, sex hormone dependent tumors of the reproductive tract and accessory organs and pregnancy. The most common side effects include headache, abdominal pain, nausea OHSS, breast pain and ovarian cyst. For complete product details, see the Full Prescribing Information and FAQs.
Prescribing Information and Important Safety Information:
Cetrotide® (cetrorelix acetate for injection) is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation. Cetrotide should be prescribed by physicians who are experienced in fertility treatment. Cetrotide® is contraindicated in women who exhibit hypersensitivity to cetrorelix acetate, mannitol or exogenous peptide hormones, who exhibit prior hypersensitivity to GnRH or any other GnRH analogs, or who are pregnant, or breast-feeding or sever renal impairment. Ovarian hyperstimulation syndrome (OHSS), with or without vascular and pulmonary complications, can occur with the use of fertility drugs. Mild and short lasting injection reactions like reddening, itching and swelling at the injection sites may occur. Nausea and headache have also been reported. For complete product details, see the Full Prescribing Information.
Prescribing Information and Important Safety Information:
Ovidrel® (choriogonadotropin alfa for injection) PreFilled Syringe is indicated for the induction of final follicular maturation and early luteinization in infertile women who have undergone pituitary desensitization and who have been appropriately pretreated with follicle stimulating hormones as part of an Assisted Reproductive Technology (ART) program such as in vitro fertilization and embryo transfer. Ovidrel® PreFilled Syringe is also indicated for the induction of ovulation (OI) and pregnancy in anovulatory infertile patients in whom the cause of infertility is functional and not due to primary ovarian failure. Ovidrel should only be used by physicians who are thoroughly familiar with infertility problems and their management. Ovidrel® is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS) in women with or without pulmonary or vascular complications. Ovidrel® is contraindicated in women who exhibit prior sensitivity to hCG preparations or their ingredients, primary ovarian failure, uncontrolled thyroid or adrenal dysfunction and pregnancy. Women who are nursing should also not use Ovidrel®. The most common side effects in women using Ovidrel® include abdominal pain, injection site reactions, nausea and vomiting. Reports of multiple births have been associated with Ovidrel treatment. For complete product details, see the Full Prescribing Information and FAQs.
To view the download, you need Adobe® Acrobat® Reader® installed. If you don’t have Adobe®, you can download it for free.
Adobe Acrobat Reader is a registered trademark of Adobe Systems Incorporated.
Luveris®, Ovidrel®, and Cetrotide® are registered trademarks of EMD Serono, Inc.
Receive additional information delivered by
your EMD Serono representative.
Request materials now
Let patients know that there are other people out there with a similar story and that Fertility LifeLines™ offers personal perspectives about infertility.
Indication:
For women, Gonal-f® (follitropin alfa for injection), Gonal-f® RFF (follitropin alfa for injection), and Gonal-f® RFF Pen (follitropin alfa injection) are indicated for (1) the induction of ovulation and pregnancy in the anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure and (2) for the development of multiple follicles in the ovulatory patient participating in an ART program.
Gonal-f® is also indicated for the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.
Important Risk Information:
These products should be prescribed only by physicians specializing in fertility or reproductive health. Use of Gonal-f®, Gonal-f® RFF, or Gonal-f® RFF Pen by women can result in multiple births.
Gonal-f®, Gonal-f® RFF, and Gonal-f® RFF Pen are potent gonadotropins capable of causing mild to severe adverse reactions, including Ovarian Hyperstimulation Syndrome (OHSS) in women with or without pulmonary or vascular complications. Gonal-f®, Gonal-f® RFF, and Gonal-f® RFF Pen are contraindicated in women and men who exhibit prior hypersensitivity to recombinant FSH preparations or one of their excipients, high levels of FSH indicating primary gonadal failure, uncontrolled thyroid or adrenal dysfunction, sex hormone-dependent tumors of the reproductive tract and accessory organs, and an organic intracranial lesion such as a pituitary tumor. Additionally, Gonal-f®, Gonal-f® RFF, or Gonal-f® Pen should not be given to women with abnormal uterine bleeding, presence or enlargement of an ovarian cyst of undetermined origin or to women who are pregnant or nursing.
The most common side effects reported in women using Gonal-f®, Gonal-f® RFF, or Gonal-f® RFF Pen include headache, abdominal pain, enlarged abdomen, ovarian cysts, nausea, and upper respiratory infections. Men using Gonal-f® have commonly reported acne, breast pain and growth, and fatigue. Injection site reactions have been reported.
Please see accompanying prescribing information below for full disclosure.
RFF: Revised Formulation Female
©2012 EMD Serono, Inc. and its affiliates.
This site contains medical information that is intended for residents of the United States only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.
This site contains information that is intended for US residents only. Canadian residents should consult the EMD Serono Canada Inc. Web site at www.emdserono.ca for information on products and services approved in Canada.
Thank you for your interest. The information provided on this site is intended for US healthcare professionals only. To help you get more information and educational resources about fertility, we are automatically directing you to FertilityLifeLines.com.
Gonal-f® Cares helps healthcare professionals care for patients by providing valuable information and educational resources. This site is intended for US healthcare professionals only.
I am a:
